Stryker Corporation $SYK Stake Lowered by Waverly Advisors LLC

Waverly Advisors LLC trimmed its position in shares of Stryker Corporation (NYSE:SYK) by 5.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 43,388 shares of the medical technology company’s stock after selling 2,440 shares during the period. Waverly Advisors LLC’s holdings in Stryker were worth $13,660,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of SYK. Sankala Group LLC acquired a new position in Stryker in the 4th quarter worth about $26,000. Godfrey Financial Associates Inc. acquired a new position in Stryker in the fourth quarter worth approximately $26,000. United Financial Planning Group LLC bought a new position in Stryker during the third quarter valued at approximately $27,000. Atlas Capital Advisors Inc. bought a new stake in Stryker in the fourth quarter worth approximately $27,000. Finally, Gables Capital Management Inc. acquired a new position in shares of Stryker during the 2nd quarter worth $25,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on SYK shares. Citizens Jmp reduced their price objective on shares of Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a research note on Monday, August 3rd. JPMorgan Chase & Co. lowered their price objective on Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. BTIG Research reduced their target price on Stryker from $371.00 to $358.00 and set a “buy” rating for the company in a report on Friday, July 31st. UBS Group started coverage on Stryker in a report on Tuesday, July 28th. They set a “buy” rating and a $400.00 price target on the stock. Finally, BMO Capital Markets started coverage on shares of Stryker in a research note on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Stock Performance

SYK opened at $276.16 on Wednesday. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The stock’s 50 day moving average price is $327.52 and its two-hundred day moving average price is $328.30. The firm has a market capitalization of $105.93 billion, a P/E ratio of 28.62, a price-to-earnings-growth ratio of 1.90 and a beta of 0.76. Stryker Corporation has a 12-month low of $275.10 and a 12-month high of $395.90.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating the consensus estimate of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The company had revenue of $6.59 billion during the quarter, compared to analysts’ expectations of $6.58 billion. During the same period in the prior year, the business earned $3.13 earnings per share. Stryker’s revenue for the quarter was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities analysts forecast that Stryker Corporation will post 15.03 earnings per share for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.3%. Stryker’s payout ratio is presently 36.48%.

Insider Activity at Stryker

In other Stryker news, insider Debra King sold 826 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the sale, the insider owned 6,210 shares in the company, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Ronda E. Stryker sold 50,000 shares of Stryker stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $340.10, for a total value of $17,005,000.00. Following the sale, the director directly owned 2,251,375 shares in the company, valued at $765,692,637.50. The trade was a 2.17% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 351,267 shares of company stock worth $118,197,701. Company insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company headquartered in Portage, Michigan. The company develops and manufactures products used by hospitals, physicians and other healthcare providers across a range of medical specialties.

Stryker’s principal businesses include orthopaedics, medical and surgical equipment, and neurovascular products. Its offerings include joint replacement and trauma implants, spinal devices, surgical instruments, operating-room equipment, endoscopy systems, surgical navigation technologies, emergency-care products and devices used to treat neurovascular conditions such as stroke.

Founded in 1941 by Dr.